| Over a week ago | ||||
Accuray Incorporated… Accuray Incorporated (ARAY) said in a regulatory filing that it is aware of media reports indicating a possible liquidity concern at Silicon Valley Bank (SVB). Accuray considers its exposure to any liquidity concern at SVB as immaterial, given that cash held at SVB is below the FDIC-insured limit of $250,000 and that Accuray holds no securities at SVB. | ||||
| Over a month ago | ||||
Accuray announced that… Accuray announced that data from the PACE-A trial indicates that stereotactic body radiation therapy, or SBRT, in comparison to surgery, better preserves urinary continence and sexual function in men with localized prostate cancer. An analysis of patient reported outcomes found that at two years, significantly fewer patients - 4.5% - treated with SBRT reported needing to use urinary pads, which manage urinary incontinence, compared with surgery - 47% -. Patients treated with SBRT also reported better sexual function after two years than those treated with surgery. SBRT is a highly targeted form of external beam radiation therapy that involves the delivery of very high doses of radiation over a small number of treatment sessions. Accuray's CyberKnife System is designed to deliver SBRT. | ||||
Still sees FY23 adjusted… Still sees FY23 adjusted EBITDA $26M-$30M. | ||||
Reports Q2 revenue… Reports Q2 revenue $114.8M, consensus $107.03M. "We have delivered another strong quarter of performance in Q2 showcasing the growing customer demand for our precision radiotherapy solutions and the excellent operational execution by the Accuray team amidst challenging macroeconomic conditions," said Suzanne Winter, Chief Executive Officer. "Our teams remain focused on advancing our innovation driven growth agenda so that we can deliver on our promise to improve the outcome and quality of life of patients diagnosed with cancer or neurological disease." | ||||
Accuray announced that… Accuray announced that the European Radiosurgery Center Munich has selected a second CyberKnife System, the latest generation CyberKnife S7 System, to enable their team to treat patients. The Center was an early adopter of CyberKnife radiosurgery. Patients eligible for radiosurgery treatments benefit from the shorter overall course of care, typically 1 to 2 sessions in Munich, compared to conventional radiation therapy which often requires 30-40 sessions. | ||||
Accuray announced that… Accuray announced that Auckland Radiation Oncology is the first center in New Zealand to treat patients with the CyberKnife System, a robotic radiation therapy device known for delivering treatments with sub-millimeter precision and accuracy in typically 1 to 5 outpatient sessions. The ARO medical care team selected the CyberKnife S7 System to provide stereotactic radiosurgery and stereotactic body radiation therapy to patients. | ||||
| Over a quarter ago | ||||
EDAP TMS SA (EDAP) hired… EDAP TMS SA (EDAP) hired Ken Mobeck as CFO of EDAP Technomed Inc., the Company's U.S. subsidiary. Prior to joining EDAP Technomed, Ken served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Incorporated (ARAY). | ||||
In a regulatory filing,… In a regulatory filing, Accuray reported that On December 1, the company informed affected employees of a cost saving initiative designed to reduce operating costs through the elimination of approximately 4.5% of its global workforce. The company expects to substantially complete the cost saving initiative in the second quarter of fiscal 2023. The company estimates the total cost of this initiative to be approximately $2.0M, which is expected to be recorded in the second quarter of fiscal 2023. | ||||
Accuray announced that… Accuray announced that the Oscar Lambret Center in Lille, France has installed its second Radixact System and the hospital's fifth Accuray radiation therapy delivery system. The hospital has enhanced both Radixact Systems with the addition of the Accuray-only ClearRT Helical Fan-Beam kVCT Imaging and Synchrony technologies, applications designed to improve treatment outcomes and versatility in the types of diseases that can be treated. The Oscar Lambret Center is part of Unicancer, the only French hospital network dedicated 100% to cancer care, research and education. | ||||
Adjusted EBITDA is still… Adjusted EBITDA is still expected in the range of $26.0M-$30.0M. | ||||
